- FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
- FDA Approves Numbrino (cocaine hydrochloride) Nasal Solution for Nasal Anesthesia
- FDA Approves Valtoco (diazepam nasal spray) as a Seizure Rescue Treatment
- FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
- FDA Approves Expanded Indication of Mycamine (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
- FDA Approves Keytruda (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
- FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes
- Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
- FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia in Adult Patients
- FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults
- FDA Approves Ubrelvy (ubrogepant) for the Acute Treatment of Migraine
- FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens
- FDA Approves Conjupri (levamlodipine maleate) for the Treatment of Hypertension
- FDA Approves Conjupri (levoamlodipine maleate) for the Treatment of Hypertension
- FDA Approves Ervebo (Ebola Zaire Vaccine, Live) for the Prevention of Disease Caused by Zaire Ebolavirus